210 related articles for article (PubMed ID: 36232331)
21. WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses.
Mortezaee K
Clin Exp Med; 2024 Jan; 24(1):15. PubMed ID: 38280119
[TBL] [Abstract][Full Text] [Related]
22. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
23. Wnt-β-Catenin Signaling in Human Dendritic Cells Mediates Regulatory T-Cell Responses to Fungi via the PD-L1 Pathway.
Karnam A; Bonam SR; Rambabu N; Wong SSW; Aimanianda V; Bayry J
mBio; 2021 Dec; 12(6):e0282421. PubMed ID: 34781737
[TBL] [Abstract][Full Text] [Related]
24. The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
Deng R; Zuo C; Li Y; Xue B; Xun Z; Guo Y; Wang X; Xu Y; Tian R; Chen S; Liu Q; Chen J; Wang J; Huang X; Li H; Guo M; Wang X; Yang M; Wu Z; Wang J; Ma J; Hu J; Li G; Tang S; Tu Z; Ji H; Zhu H
Cell Mol Immunol; 2020 Nov; 17(11):1163-1179. PubMed ID: 32963356
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
[TBL] [Abstract][Full Text] [Related]
27. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
30. Low-density lipoprotein receptor-related protein 8 facilitates the proliferation and invasion of non-small cell lung cancer cells by regulating the Wnt/β-catenin signaling pathway.
Fang Z; Zhong M; Zhou L; Le Y; Wang H; Fang Z
Bioengineered; 2022 Mar; 13(3):6807-6818. PubMed ID: 35246020
[TBL] [Abstract][Full Text] [Related]
31. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
32. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
[TBL] [Abstract][Full Text] [Related]
33. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
Zhang Z; Yang Y; Zhang X
Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
[TBL] [Abstract][Full Text] [Related]
34. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
35. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.
Cui Y; Zhang F; Zhu C; Geng L; Tian T; Liu H
Oncotarget; 2017 Mar; 8(11):17785-17794. PubMed ID: 28147312
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
37. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
[TBL] [Abstract][Full Text] [Related]
38. The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer.
Aghbash PS; Hemmat N; Baradaran B; Mokhtarzadeh A; Poortahmasebi V; Oskuee MA; Baghi HB
Oncol Res; 2022; 30(3):99-116. PubMed ID: 37305016
[TBL] [Abstract][Full Text] [Related]
39. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]